Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
[Proton therapy for head and neck cancers] journalArticle 2017 Blanchard, P.; Frank, S. J.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial journalArticle 2017 Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma journalArticle 2017 Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) journalArticle 2017 Fresneau, Brice; Hackshaw, A.; Hawkins, D. S.; Paulussen, M.; Anderson, J. R.; Judson, I.; Litière, S.; Dirksen, U.; Lewis, I.; van den Berg, H.; Gaspar, N.; Gelderblom, H.; Whelan, J.; Boddy, A. V.; Wheatley, K.; Pignon, J. P.; De Vathaire, F.; Le Deley, M. C.; Le Teuff, G.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies journalArticle 2016 Postel-Vinay, S.; Aspeslagh, S.; Lanoy, E.; Robert, C.; Soria, J. C.; Marabelle, A.
Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study journalArticle 2016 Charles, C.; Razavi, D.; Bungener, C.; Mateus, C.; Lanoy, E.; Verschoore, M.; Dauchy, S.; Robert, C.
New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues journalArticle 2016 Martelli, N.; van den Brink, H.; Borget, I.
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group journalArticle 2016 Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C.
Hypofractionation for prostate cancer: a word of caution journalArticle 2016 Bossi, A.; Blanchard, P.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial journalArticle 2016 Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G.
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials journalArticle 2016 Kempf, E.; Lemoine, N.; Tergemina-Clain, G.; Turpin, A.; Postel-Vinay, S.; Lanoy, E.; Soria, J. C.; Massard, C.; Hollebecque, A.
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes journalArticle 2016 Sio, T. T.; Lin, H. K.; Shi, Q.; Gunn, G. B.; Cleeland, C. S.; Lee, J. J.; Hernandez, M.; Blanchard, P.; Thaker, N. G.; Phan, J.; Rosenthal, D. I.; Garden, A. S.; Morrison, W. H.; Fuller, C. D.; Mendoza, T. R.; Mohan, R.; Wang, X. S.; Frank, S. J.
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours journalArticle 2016 Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K.
Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in Eur J Cancer 51 (2015), 1570-1579 journalArticle 2016 Blanchard, P.; Ribassin-Majed, L.; Lee, A.; Pignon, J. P.
Human metapneumovirus in patients hospitalized with acute respiratory infections: A meta-analysis journalArticle 2016 Lefebvre, A.; Manoha, C.; Bour, J. B.; Abbas, R.; Fournel, I.; Tiv, M.; Pothier, P.; Astruc, K.; Aho-Glele, L. S.
Innovations for phase I dose-finding designs in pediatric oncology clinical trials journalArticle 2016 Doussau, A.; Geoerger, B.; Jimenez, I.; Paoletti, X.